Skip to main content
Equibles
INGN logo

INGN · Inogen Inc

Track INGN — free

Use INGN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research INGN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.69 +0.07 (+1.25%) At close · Nov 13
Russell 2000 member Rebalance outlook locked
Market Cap
$147.95M
Shares
26.00M
Volume · Nov 13 238.18K Avg daily vol (3M) 312.43K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$5.69 Open$5.60 Day$5.55–5.71 52W close$5.09–7.35 Avg vol 30d296K Short int1.4M · 5.4% of shares · 5.8d Short vol36% Last earningsNov 5, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 9

Up next

Next earnings call
Feb 23, 2027 Est · unconfirmed · in 14 wks
Q3 2026 earnings call transcript
call held Nov 5, 2026
Play latest call

Latest documents

2026
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Rental divestiture closes as continuing-operations loss widens

Inogen completed its U.S. oxygen rental business sale to Rotech for up to $24.8 million on November 2, 2026. Third-quarter revenue fell $1.9 million, or 2.4%, while continuing-operations loss widened by $11.2 million following a goodwill impairment.

Revenue $77.19M ▼ 2.4% Net loss $16.16M Diluted EPS -$0.61
Read from the MD&A section
4 source passages
On September 29, 2026, we entered into an Asset Purchase Agreement, or the Purchase Agreement, with Rotech Healthcare Inc., or Rotech, pursuant to which we agreed to sell to Rotech certain assets used or held for use solely in the operation of our United States oxygen rental business, or the Rental Business, and to assist in transferring related patient records, or the Transaction. On November 2, 2026, we completed the Transaction for an aggregate purchase price of up to $24.8 million, payable in six installments commencing on January 4, 2027 and subject to a post-closing reconciliation. Revenue decreased $1.9 million, or 2.4%, for the three months ended September 30, 2026 from the three months ended September 30, 2025. Loss from continuing operations increased $11.2 million, or 309.5%, for the three months ended September 30, 2026 from the three months ended September 30, 2025. Open the document at this passage
Nov 5
Earnings call
Revenue falls 2.4%; $20 million savings program announced

Inogen reported revenue for the third quarter of 2026 down 2.4% year over year and announced a $20 million annualized cost-savings program, while U.S. sales rose 3.8% and the U.S. oxygen rental divestiture closed for up to $24.8 million.

5 source passages
Earlier today, Inogen released financial results for the third quarter of 2026. Total revenue in the third quarter of 2026 was $77.2 million, a decrease of 2.4% from $79.1 million in the prior year period, or a decrease of 3.2% on a constant currency basis. U.S. sales were $42.2 million, up 3.8%, reflecting distributor demand and new product contributions. Adjusted net loss from continuing operations was $0.4 million in the third quarter of 2026, and we announced an additional $20 million cost savings program to accelerate profitability. The transaction closed on November 2nd for a total estimated cash consideration of up to $24.8 million, which we expect to receive in the first half of 2027. Open the document at this passage
Nov 5
Current report 8-K Events of Oct 30
Andy Reding appointed CEO as quarterly loss widens

Inogen appointed Andy Reding President and CEO; third-quarter revenue was $77.2 million, while GAAP loss from continuing operations was $14.8 million, compared with $3.6 million a year earlier. The company targets approximately $20 million in annualized savings by the end of 2027.

Completed an acquisition or sale of assets, Financial results, Director or officer change, or executive pay, Regulation FD disclosure, Other events Read from the first part of this long document
4 source passages
BEVERLY, Mass., November 5, 2026 – Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that its Board of Directors has appointed Andy Reding, the Company’s Chief Operating Officer, as President and Chief Executive Officer and a member of the Board of Directors. GAAP total revenue from continuing operations of $77.2 million in the third quarter of 2026, reflecting the divestiture of the U.S. oxygen rental business Reported GAAP loss from continuing operations of $14.8 million in the third quarter of 2026 compared to $3.6 million in the prior-year period. Adjusted loss from continuing operations was $0.4 million in the third quarter of 2026 compared to adjusted earnings of $1.2 million in the prior-year period Initiated a cost reduction program beginning in the fourth quarter of 2026 that is expected to generate approximately $20 million of annualized savings by the end of 2027 Open the document at this passage
Sep 30
Current report 8-K Events of Sep 28
Entered into a material agreement, Regulation FD disclosure, Other events

Inogen agreed to sell substantially all assets of its U.S. oxygen rental business to Rotech Healthcare Inc. for up to $24.8 million. If the transaction closes, its share repurchase authorization will rise to $45.0 million and expire June 30, 2028.

Aug 7
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $95.08M ▲ 3.0% Net loss $3.85M Diluted EPS -$0.14
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$352.41M
Trailing 12 months
Net income (TTM)
−$35.46M
Trailing 12 months
Revenue growth YoY
-2.4%
Year over year
Operating margin
-11.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-7.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-2.3%
Year over year · fewer shares
Price change (1Y)
-17.3%
Trailing year
Short interest
5.4%
Latest settlement · 5.8 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▲5.5% $80.08M −$9.76M '24 Q4* ▲5.5% $82.28M −$6.17M '25 Q1 ▲4% $92.28M −$4.15M '25 Q2 ▼11% $79.09M −$5.29M '25 Q3 ▲18.7% $95.02M −$7.13M '25 Q4* ▲3.4% $85.11M −$8.32M '26 Q1 ▲3% $95.08M −$3.85M '26 Q2 LATEST ▼2.4% $77.19M −$16.16M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

AI Brief

Q3 FY26 earnings call · Nov 5, 2026
Q3 FY26

TL;DR. U.S. sales and POC unit volume grew, Inogen completed the rental divestiture, launched a cost-reduction program, increased R&D investment and expanded its buyback authorization. However, total and international revenue declined, adjusted profitability weakened, full-year adjusted loss is expected to be $7 million to $8 million, GAAP loss expanded with a $10.6 million goodwill impairment, and operating cash flow was negative.

Bullish
  • + U.S. sales returned to year-over-year growth, rising 3.8% to $42.2 million. new
  • + POC unit volume increased nearly 6% to 51,900 units and 9.5% year to date. new
  • + The U.S. oxygen rental divestiture simplified the business, provides up to $24.8 million of cash consideration and expands patient access through a national distribution network. new
  • + Inogen held $97.7 million of cash and investments with no debt and increased its buyback authorization by $15 million to $45 million. new
  • + Adjusted R&D expense increased 13.3% to $4.4 million to support clinical evidence and new product development for long-term differentiation and growth. new
  • + Inogen initiated a cost-reduction program expected to generate approximately $20 million of annualized savings by the end of 2027. new
Bearish
  • − Total revenue decreased 2.4% to $77.2 million, or 3.2% on a constant-currency basis. new
  • − International sales declined 9% due to softer European customer capital spending, and management expects the trend to continue into the fourth quarter. new
  • − Inogen guided to fourth-quarter revenue of $65 million to $68 million, full-year revenue of $298 million to $301 million and a full-year adjusted loss from continuing operations of $7 million to $8 million. new
  • − GAAP loss from continuing operations increased to $14.8 million from $3.6 million, including a $10.6 million non-cash goodwill impairment. new
  • − Operating cash flow was negative $4.5 million because of higher working capital. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −9%
below
Price vs 50-day avg −5%
below
RSI (14) 37
neutral
MACD trend Negative
52-week position 27%
mid-range
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Very Weak
1-month return −9%
trailing
6-month return −14%
trailing
YTD return −15%
this year
Relative strength −14%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $6 › 200d $6 — 200d above 50d
Institutional flow Accumulating
105 of 129 funds reported for Sep 30 · net +95.4K sh shares · +16 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
5.40% of shares out · ▼ -8.3% MoM · 5.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
129 holders — near 3-yr low, contrarian setup
Squeeze score 60
elevated · 0–100
Fundamentals
Strong
Revenue growth +4%
Y/Y
Gross margin 44%
contracting
EPS growth +43%
Y/Y
Free cash flow $-13.7M
Buyback $45.0M
authorized
Quant / Vol
risk profile
Very High
Volatility 45%
annualized · 1-yr
Max drawdown −31%
past year
ATR 6.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 5 of last 8
Latest guidance · from the Earnings Call filed Aug 6, 2026
Total revenue · full year 2026 Maintained $355M – $361M
Jun 30, 2026 $355M – $361M changed to Aug 6, 2026 $355M – $361M
prior FY $348.67M midpoint +2.7% Y/Y
Adjusted EBITDA · full year 2026 Non-GAAP Maintained $4M
Jun 30, 2026 $4M changed to Aug 6, 2026 $4M
Prior guidance period ended · from the Earnings Call filed Aug 6, 2026
Reported revenue · third quarter of 2026 $92.4M
Guided vs delivered · last 8 settled
Reported revenue third quarter of 2026
guided $92.4M
$77.19M Miss −16.5%
Reported revenue second quarter of 2026
guided $94M – $97M
$95.08M In line
Full year revenue full year 2025
guided $354M – $357M
$348.67M Miss −1.9%
Reported revenue fourth quarter 2025
guided $87M – $90M
$121.94M Beat +37.8%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−9% Bearish
Price vs 50-day avg
−5% Bearish
RSI (14)
37 Neutral
MACD trend
Negative Bearish
52-week position
27% Neutral
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $6 › 200d $6 — 200d above 50d
Institutional flow Accumulating
105 of 129 funds reported for Sep 30 · net +95.4K sh shares · +16 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
5.40% of shares out · ▼ -8.3% MoM · 5.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
129 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $5 Now $6 · 27% Range high $7
vs 200-day avg -9% vs 50-day avg -5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
EBITDA (non-GAAP) non-GAAP -$168K Three months ended June 30, 2026 filing —
Adjusted EBITDA non-GAAP $2.4M second quarter of 2026 —
GAAP → non-GAAP reconciliation
EBITDA (non-GAAP) -$168K (the result of another reconciliation in this filing)
+$1.77M Stock-based compensation expense
+$214K Restructuring-related charges
+$580K Stockholder engagement and proxy defense costs
= Adjusted EBITDA (non-GAAP) $2.4M
Net rental patients as of period-end 45,500 Q2 2026 —
Portable units sold 99,600 Six months ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
INGN
Inogen Inc
this stock
$147.95M -15.3% +3.9% — 5.4%
ABT
Abbott Laboratories
 $187.95B -13.4% +5.7% 40.5 1.1%
MDT
Medtronic plc
 $131.57B +7.1% +8.4% 25.3 1.8%
SYK
Stryker Corp
 $117.88B -11.9% +11.2% 33.0 1.7%
BSX
Boston Scientific Corp
 $64.27B -53.5% +12.5% 18.8 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
138
% held
74.3%
Reported
105 of 129
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
161
View
Short & Settlement
Short Interest Falling
Shares short
1.4M
Days to cover
5.8d
Change
-127.7K sh
View
Short Volume
Short vol %
36%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
734
Value
$4.2K
As of
Oct 7, 2026
View
Off-Exchange
Off-exchange %
31.9%
Week of
Oct 5, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$348.7M
Net income (FY)
$-22.7M
EPS diluted
$-0.86
View
Buybacks
Authorized
$45.0M
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 9, 2026
This year
19

Inogen completed its U.S. oxygen rental business sale to Rotech for up to $24.8 million on November 2, 2026. Third-quarter revenue fell $1.9 million, or 2.4%, while continuing-operations loss widened by $11.2 million following a goodwill impairment.

View
Proposed Sales
Value
$70.6K
Shares
10.9K
Filed
Jul 1, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
Inogen Announces Leadership Trans…
Published
Nov 5, 2026
View

Performance

5D 20D 120D MTD YTD
INGN -5.6% -9.0% -13.5% -17.1% -15.3%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -8.2% -7.8% -14.0% -16.9% -26.0%

Capital returns

Buyback program · as of Nov 2, 2026
Authorized
$45.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1294133 CUSIP 45780L104 13F (30d) 104 filings 90 filers Visit website Investor relations